返回 Agenda
Session Chair(s)
Arthur A. Levin, PHD
Distinguished Scientist
Avidity Biosciences, United States
Barbara Wilcox, PHD
Pharmacologist, OMPT, ODEI, DNP, OND, CDER
FDA, United States
Speaker(s)
Development of siRNA Lipid Nanoparticle Formulations
Garvin L Warner, PHD
Alnylam Pharmaceuticals, United States
Vice President, Preclinical Development
Oligonucleotide Toxicity and its Relationship to Compound Structure: FDA Experience from Nonclinical Testing
Paul C. Brown, PHD
FDA, United States
Associate Director for Pharmacology and Toxicology, OND, CDER
Potential Attributes of a Platform Technology: How Best to Capitalize on Cumulative MOE Oligonucleotide Safety Data
Scott Henry, PHD
Ionis Pharmaceuticals, Inc., United States
Senior Vice President, Nonclinical Development